None
Quote | Gossamer Bio Inc. (NYSE:GOSS)
Last: | $ |
---|---|
Change Percent: | 1.20% |
Open: | $15.02 |
Close: | $15.21 |
High: | $15.22 |
Low: | $14.79 |
Volume: | 313,154 |
Last Trade Date Time: | 02/12/2020 04:40:17 pm |
News | Gossamer Bio Inc. (NYSE:GOSS)
2024-06-24 17:57:36 ET More on Gossamer Bio Seeking Alpha’s Quant Rating on Gossamer Bio Historical earnings data for Gossamer Bio Financial information for Gossamer Bio Read the full article on Seeking Alpha For further details see: Gossam...
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
Message Board Posts | Gossamer Bio Inc. (NYSE:GOSS)
Subject | By | Source | When |
---|---|---|---|
Agreed! | Dutch4 | investorshub | 03/24/2023 5:03:33 PM |
Institutionals shorting this unmercilessly. Three trades totalling | hippityhop | investorshub | 12/22/2022 9:20:39 PM |
This is a 100/200 percenter in next 3 | hippityhop | investorshub | 12/19/2022 4:53:28 PM |
Raymond James Initiates Coverage On Gossamer Bio with | crudeoil24 | investorshub | 04/20/2022 11:43:11 PM |
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. | crudeoil24 | investorshub | 04/20/2022 11:41:45 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...